

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Kimberly A. Gillis et al.

Application No.: 09/996,529 -- 3553

Filed: November 28, 2001

For: Expression Analysis of Inhibitor of
Differentiation Nucleic Acids And Polypeptides
Useful In The Diagnosis And Treatment of Prostate
Cancer

Attorney Docket No.: 102729-14

Group Art Unit: 1642

Examiner: Davis, Minh Tam B.

STATEMENTS UNDER 37 C.F.R § 1.821 and 37 C.F.R § 1.825

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

I hereby state that the content of the computer readable Sequence Listing accompanying this Statement is the same as the content of the Sequence Listing submitted in accordance with 37 C.F.R §1.821(c) and (e), respectively.

Additionally, I hereby state that the content of the amendatory material contained in the Sequence Listing, specifically SEQ ID NOS: 4 and 5, accompanying this Statement is the same material which was incorporated by reference in the originally filed application in accordance with 37 C.F.R. § 1.825. Accordingly, the Amendment to the Sequence Listing contains no new matter.

Respectfully submitted,

NUTTER, MCCLENNEN & FISH, LLP


Thomas J. Engelenner, Reg. No. 28,711
Attorney for Applicants
World Trade Center West
155 Seaport Boulevard
Boston, MA 02210-2604
Tel: (617) 439-2948
Fax (617) 310-9948

Dated: October 19, 2004